In last trading session, Astrazeneca plc ADR (NASDAQ:AZN) saw 4.1 million shares changing hands with its beta currently measuring 0.51. Company’s recent per share price level of $66.26 trading at $0.07 or 0.11% at ring of the bell on the day assigns it a market valuation of $205.43B. That closing price of AZN’s stock is at a discount of -15.54% from its 52-week high price of $76.56 and is indicating a premium of 8.74% from its 52-week low price of $60.47. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.6 million shares which gives us an average trading volume of 6.21 million if we extend that period to 3-months.
Astrazeneca plc ADR (NASDAQ:AZN) trade information
Upright in the green during last session for gaining 0.11%, in the last five days AZN remained trading in the red while hitting it’s week-highest on Friday, 03/22/24 when the stock touched $66.26 price level, adding 0.87% to its value on the day. Astrazeneca plc ADR’s shares saw a change of -1.62% in year-to-date performance and have moved -0.08% in past 5-day. Astrazeneca plc ADR (NASDAQ:AZN) showed a performance of 3.32% in past 30-days. Number of shares sold short was 9.26 million shares which calculate 1.13 days to cover the short interests.
Astrazeneca plc ADR (AZN) estimates and forecasts
Statistics highlight that Astrazeneca plc ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -1.13% of value to its shares in past 6 months, showing an annual growth rate of 12.12% while that of industry is 4.50. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 30.20% in the current quarter and calculating 25.00% increase in the next quarter. This year revenue growth is estimated to rise 10.90% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $11.98 billion for the same. And 3 analysts are in estimates of company making revenue of $12.46 billion in the next quarter that will end on Jun 2024. Company posted $10.55 billion and $10.96 billion of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 13.50% while estimating it to be 13.70% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 17.72% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 12.38% while estimates for its earnings growth in next 5 years are of 12.80%.
AZN Dividends
Astrazeneca plc ADR is more likely to be releasing its next quarterly report in April and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Astrazeneca plc ADR (NASDAQ:AZN)’s Major holders
Insiders are in possession of 0.00% of company’s total shares while institution are holding 16.80 percent of that, with stock having share float percentage of 16.80%. Investors also watch the number of corporate investors in a company very closely, which is 16.80% institutions for Astrazeneca plc ADR that are currently holding shares of the company. Price (T.Rowe) Associates Inc is the top institutional holder at AZN for having 52.85 million shares of worth $3.78 billion. And as of Jun 29, 2023, it was holding 2.01% of the company’s outstanding shares.
The second largest institutional holder is Wellington Management Group, LLP, which was holding about 49.13 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 1.87% of outstanding shares, having a total worth of $3.52 billion.
On the other hand, Vanguard/Primecap Fund and Washington Mutual Investors Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 25.66 million shares of worth $1.84 billion or 0.98% of the total outstanding shares. The later fund manager was in possession of 22.46 million shares on Sep 29, 2023, making its stake of worth around $1.52 billion in the company or a holder of 0.86% of company’s stock.
